RhumbLine Advisers
CTXR icon

RhumbLine Advisers’s Citius Pharmaceuticals CTXR Stock Holding History

RhumbLine Advisers’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,202
Closed -$17.5K – 4229
2024
Q2 		$17.5K Sell
1,202
-5,072
-81% -$90.9K ﹤0.01% 3890
2024
Q1 		$141K Buy
6,274
+269
+4% +$4.91K ﹤0.01% 3328
2023
Q4 		$114K Sell
6,005
-55
-0.9% -$1.04K ﹤0.01% 3411
2023
Q3 		$104K Buy
6,060
+291
+5% +$6.92K ﹤0.01% 3451
2023
Q2 		$173K Buy
+5,769
New +$190K ﹤0.01% 3313
2022
Q2 		– Sell
-4,992
Closed -$223K – 3126
2022
Q1 		$223K Buy
4,992
+833
+20% +$32.9K ﹤0.01% 2731
2021
Q4 		$160K Sell
4,159
-158
-4% -$7.17K ﹤0.01% 2881
2021
Q3 		$219K Buy
4,317
+156
+4% +$7.83K ﹤0.01% 2876
2021
Q2 		$362K Buy
+4,161
New +$250K ﹤0.01% 2713

Other funds holding CTXR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CCC
Chelsea Counsel Company Los Angeles, California $225M AUM 45.99% 1-Year Est. Return

RhumbLine Advisers's CTXR Position: Q3 2024 in Review

RhumbLine Advisers sold out of Citius Pharmaceuticals (CTXR) in Q3 2024, closing a stake of 1,202 shares — an estimated $17.5K sold.

RhumbLine Advisers first reported a position in CTXR in Q2 2021 and held it in 9 quarters. The position peaked at $362K in Q2 2021. 57 funds tracked by Wall St. Rank hold CTXR as of Q3 2024.

  • RhumbLine Advisers reported no remaining Citius Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 1,202 Citius Pharmaceuticals shares in Q3 2024, an estimated $17.5K.
  • RhumbLine Advisers first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 9 quarters.
  • RhumbLine Advisers's Citius Pharmaceuticals position peaked at $362K in Q2 2021.
  • 57 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.